Antiproliferative effect of lapatinib in HER2-Positive and HER2-Negative/HER3-High breast cancer: Results of the presurgical randomized MAPLE Trial (CRUK E/06/039)

Clinical Cancer Research

Volumn 21, Issue 13, 2015, Pages 2932-2940

  Leary, Alexandra ^a   Evans, Abigail ^b   Johnston, Stephen R D ^c   A'Hern, Roger ^c   Bliss, Judith M ^c   Sahoo, Rashmita ^d   Detre, Simone ^e   Haynes, Benjamin P ^c   Hills, Margaret ^e   Harper Wynne, Catherine ^f   Bundred, Nigel ^g   Coombes, Gill ^c   Smith, Ian ^c   Dowsett, Mitch ^c,e  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b POOLE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d DNA Electronics Ltd   (United Kingdom)

^e INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^f Maidstone and Tunbridge Well NHS Trust   (United Kingdom)

^g MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHIREGULIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIREGULIN; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LAPATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NEU DIFFERENTIATION FACTOR; PLACEBO; PROGESTERONE RECEPTOR; PROTEIN KINASE B; RHO FACTOR; STATHMIN; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 3; ERBB2 PROTEIN, HUMAN; ERBB3 PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE; TUMOR MARKER;

ADULT; AGED; AMPHIREGULIN GENE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DIARRHEA; DRUG EFFECT; DRUG RESPONSE; DRUG SAFETY; EARLY CANCER; EGFR GENE; EPIREGULIN GENE; ESR1 GENE; FEASIBILITY STUDY; FEMALE; HER2 GENE; HER2 NEGATIVE BREAST CANCER; HER2 POSITIVE BREAST CANCER; HER3 GENE; HER3 HIGH BREAST CANCER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; IN VIVO STUDY; INFECTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUREGULIN GENE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RASH; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT DURATION; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PATHOLOGY; PREOPERATIVE PERIOD; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; PREOPERATIVE PERIOD; QUINAZOLINES; RECEPTOR, ERBB-2; RECEPTOR, ERBB-3; TREATMENT OUTCOME;

EID: 84941966977     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1428     Document Type: Article

References (29)

1. Blackwell KL, Burstein HJ, Storniolo AM, RugoHS, Sledge G, Aktan G, et al. Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012;30:2585-92.
2. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008;112:533-43.
3. Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, et al. Lapatinib combinedwith letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538-46.
4. Johnston S, Trudeau M, Kaufman B, Boussen H, Blackwell K, LoRusso P, et al. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy. J Clin Oncol 2008;26: 1066-72.
5. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
6. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer-A study from the IMPACT trialists. J Clin Oncol 2005;23:2477-92.
7. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, Griffith C, et al. Shortterm changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:951s-8s.
8. The Australian and New Zealand Breast Cancer Trials Group, Clinical Oncological Society of Australia. A randomized trial in postmenopausal patients with advanced breast cancer comparing endocrine and cytotoxic therapy given sequentially or in combination. JClin Oncol 1986;4:186-93.
9. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment ofKi67 in breast cancer: recommendations fromthe International Ki67 in Breast Cancer working group. J Natl Cancer Inst 2011;103:1656-64.
10. Guix M, Granja Nde M, Meszoely I, Adkins TB, Wieman BM, Frierson KE, et al. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers. J Clin Oncol 2008;26:897-906.
11. Martin LA, DaviesGL,Weigel MT, Betambeau N, Hills MJ, Salter J, et al. Presurgical study of the biological effects of the selective cyclo-oxygenase-2 inhibitor celecoxib in patients with primary breast cancer. Breast Cancer Res Treat 2010;123:829-36.
12. Pinhel IF, Macneill FA, Hills MJ, Salter J, Detre S, A'Hern R, et al. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer. Breast Cancer Res 2010;12:R76.
13. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007;131:18-43.
14. Detre S, Saclani Jotti G, Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol 1995;48:876-8.
15. Saal LH, Johansson P, Holm K, Gruvberger-Saal SK, She QB, Maurer M, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A 2007;104:7564-9.
16. Coombes RC, Tat T,Miller ML, Reise JA,Mansi JL, Hadjiminas DJ, et al. An open-label study of lapatinib in women with HER-2-negative early breast cancer: the lapatinib pre-surgical study (LPS study). Ann Oncol 2013;24: 924-30.
17. Paik S, Kim C, Jeong J, Geyer CE, Romond EH, Mejia-Mejia O, et al. ASCO annual meeting proceedings: benefit from adjuvant trastuzumab may not be confined to patients with IHC 3+ and/or FISH-positive tumors: Central testing results from NSABP B-31, Part I. J Clin Oncol 2007;25:511.
18. Carey LA, Berry DA, Ollila D, Lyndsay H, Krop IE, Weckstein D, et al. Clinical and translational results of CALGB 40601: A neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer. J Clin Oncol 2013;31(suppl, abstr 500).
19. McIntyre E, Blackburn E, Brown PJ, Johnson CG, Gullick WJ. The complete family of epidermal growth factor receptors and their ligands are coordinately expressed in breast cancer. Breast Cancer Res Treat 2010; 122:105-10.
20. Hayes NV, Gullick WJ. The neuregulin family of genes and their multiple splice variants in breast cancer. J Mammary Gland Biol Neoplasia 2008;13:205-14.
21. Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 2005;5:341-54.
22. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, Balko JM, et al. Trastuzumab has preferential activity against breast cancers driven byHER2 homodimers. Cancer Res 2011;71:1871-82.
23. Stern DF. ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer. J Mammary Gland Biol Neoplasia 2008;13: 215-23.
24. Liu J, Nethery D, Kern JA. Neuregulin-1 induces branching morphogenesis in the developing lung through a P13K signal pathway. Exp Lung Res 2004;30:465-78.
25. Lazrek Y, Dubreuil O, Garambois V, Gaborit N, Larbouret C, Le Clorennec C, et al. Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation. Neoplasia 2013;15:335-47.
26. Balz LM, Bartkowiak K, Andreas A, Pantel K, Niggemann B, Zanker KS, et al. The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-gamma1 signalling in breast cancer cell migration and dissemination. J Pathol 2012;227: 234-44.
27. O'Brien NA, Browne BC, Chow L, Wang Y, Ginther C, Arboleda J, et al. Activated phosphoinositide 3-kinase/AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 2010;9:1489-502.
28. Waterhouse BR, Gijsen M, Barber PR, Tullis ID, Vojnovic B, Kong A. Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexaconjugated secondary antibodies in relation to targeted therapies in cancers. Oncotarget 2011;2:728-36.
29. DeFazio-Eli L, Strommen K, Dao-Pick T, Parry G, Goodman L, Winslow J. Quantitative assays for the measurement of HER1-HER2 heterodimerization and phosphorylation in cell lines and breast tumors: applications for diagnostics and targeted drug mechanism of action. Breast Cancer Res 2011;13:R44.